Kefir: A protective dietary supplementation against viral infection
- PMID: 33186795
- PMCID: PMC7655491
- DOI: 10.1016/j.biopha.2020.110974
Kefir: A protective dietary supplementation against viral infection
Abstract
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a recently discovered coronavirus termed 'severe acute respiratory syndrome coronavirus 2' (SARS-CoV-2). Several scholars have tested antiviral drugs and compounds to overcome COVID-19. 'Kefir' is a fermented milk drink similar to a thin yogurt that is made from kefir grains. Kefir and its probiotic contents can modulate the immune system to suppress infections from viruses (e.g., Zika, hepatitis C, influenza, rotaviruses). The antiviral mechanisms of kefir involve enhancement of macrophage production, increasing phagocytosis, boosting production of cluster of differentiation-positive (CD4+), CD8+, immunoglobulin (Ig)G+ and IgA+ B cells, T cells, neutrophils, as well as cytokines (e.g., interleukin (IL)-2, IL-12, interferon gamma-γ). Kefir can act as an anti-inflammatory agent by reducing expression of IL-6, IL-1, TNF-α, and interferon-γ. Hence, kefir might be a significant inhibitor of the 'cytokine storm' that contributes to COVID-19. Here, we review several studies with a particular emphasis on the effect of kefir consumption and their microbial composition against viral infection, as well as discussing the further development of kefir as a protective supplementary dietary against SARS-CoV-2 infection via modulating the immune response.
Keywords: Anti-inflammatory; Antiviral activity; Coronaviru; Immune system; Kefir.
Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Conflict of interest statement
The authors report no declarations of interest.
Figures
References
-
- Jamison D.T., Breman J.G., Measham A.R., Alleyne G., Claeson M., Evans D.B. The World Bank; 2006. Disease Control Priorities in Developing Countries. - PubMed
-
- Pyrc K., Berkhout B., van der Hoek L. Identification of new human coronaviruses. Expert Rev. Anti. Ther. 2007;5(2):245–253. - PubMed
-
- Gerna G., Campanini G., Rovida F., Percivalle E., Sarasini A., Marchi A. Genetic variability of human coronavirus OC43‐, 229E‐, and NL63‐like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients. J. Med. Virol. 2006;78(7):938–949. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
